Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > an absolute fiasco
View:
Post by antoninus on Jul 14, 2011 10:10am

an absolute fiasco

talk about one's "investment" going to waste....

we all sit here watching it spiral downward day after day year after year....and not once has the ceo's competency been called into question in any serious way....

shouldn't he be removed by now given the stocks pathetic performance for years on end? In any serious public company south of the border, this behaviour would NOT be tolerated.

Bob, for the good of everyone- step down. appoint someone from outside who actually has experience in biotech, who has real relationships in the field and KNOWS how to get things done. You will only help your own investment if you did this..staying there only hurts your chances of pulling out of this morass.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities